60 Degrees Pharmaceuticals, Inc. (SXTP:NASDAQ) closed at $0.625 on October 27, 2026, down 26.13% on the day. The stock trades 92.7% below its 52-week high of $8.62 and 2.5% above its 52-week low of $0.610. Over the past year, it lost 85.3%. 60 Degrees Pharmaceuticals, Inc. is part of the Health Care sector.
In 252 trading sessions since October 24, 2025, SXTP closed higher on 91 days (36%). Its best day was January 22, 2026 (+152.00%) and its worst was October 6, 2026 (-22.92%). The stock moved 10% or more in a single session 28 times. It opened at least 5% above the previous day's high 3 times.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.
Find more stocks like SXTP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.